Phase II study of cytarabine in Hodgkin's disease. The EORTC Lymphoma Cooperative Group.
Cytarabine was administered to 24 patients with previously treated Hodgkin's disease in the EORTC Lymphoma Cooperative Group. The drug was administered at the dose of 80 mg/m2 subcutaneously twice a day on 5 consecutive days every 3 weeks. The overall response rate was 17.6% (3 responses among 17 evaluable patients) with a short duration (2-6 months). The main toxicity was myelosuppression. Our experience in the EORTC Lymphoma Cooperative Group could not demonstrate a significant activity at this dose and schedule in Hodgkin's disease.
Thomas
J
J
Division of Oncology, University Hospital, St Rafaël, Leuven, Belgium.
de Pauw
B
B
Hagenbeek
A
A
Somers
R
R
Carde
P
P
Tirelli
U
U
Duez
N
N
D000328:Adult; D003561:Cytarabine / Q000009:adverse effects / Q000627:therapeutic use*; D004334:Drug Administration Schedule; D004341:Drug Evaluation; D005260:Female; D006689:Hodgkin Disease / Q000188:drug therapy*; D006801:Humans; D008297:Male; D008875:Middle Aged
D003561:Cytarabine